{"id":250090,"date":"2023-01-24T00:00:00","date_gmt":"2023-01-24T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidon0060-biopharma-acute-lymphoblastic-leukemia-epidemiology\/"},"modified":"2026-03-31T10:35:06","modified_gmt":"2026-03-31T10:35:06","slug":"epidon0060-biopharma-acute-lymphoblastic-leukemia-epidemiology-mature-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidon0060-biopharma-acute-lymphoblastic-leukemia-epidemiology-mature-markets\/","title":{"rendered":"Acute Lymphoblastic Leukemia &#8211; Epidemiology &#8211; Mature Markets"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of acute lymphoblastic leukemia (<abbr data-abbreviation-entity=\"6237\" title=\"acute lymphoblastic leukemia\">ALL<\/abbr>) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of <abbr title=\"acute lymphoblastic leukemia\">ALL<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy in the developed world.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr title=\"acute lymphoblastic leukemia\">ALL<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>Of all people diagnosed with <abbr title=\"acute lymphoblastic leukemia\">ALL<\/abbr>, how many in each country in the developed world are drug-treated?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"acute lymphoblastic leukemia\">ALL<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>In total, Clarivate Epidemiology forecasts 41 <abbr data-abbreviation-entity=\"6237\" title=\"acute lymphoblastic leukemia\">ALL<\/abbr> patient populations, including the following:<\/p>\n<ul class=\"round-bullets\">\n<li>Second-line B-cell receptor-Abelson leukemia virus (<abbr data-abbreviation-entity=\"5618\" title=\"B-cell receptor\">BCR<\/abbr>&#8211;<abbr data-abbreviation-entity=\"7913\" title=\"Abelson leukemia virus\">ABL<\/abbr>)-positive drug-treatable older adult population.<\/li>\n<li>Second-line <abbr data-abbreviation-entity=\"5618\" title=\"B-cell receptor\">BCR<\/abbr>&#8211;<abbr data-abbreviation-entity=\"7913\" title=\"Abelson leukemia virus\">ABL<\/abbr>-negative drug-treatable older adult population.<\/li>\n<li>Second-line <abbr data-abbreviation-entity=\"5618\" title=\"B-cell receptor\">BCR<\/abbr>&#8211;<abbr data-abbreviation-entity=\"7913\" title=\"Abelson leukemia virus\">ABL<\/abbr>-positive drug-treatable adolescent and young adult population.<\/li>\n<li>Second-line <abbr data-abbreviation-entity=\"5618\" title=\"B-cell receptor\">BCR<\/abbr>&#8211;<abbr data-abbreviation-entity=\"7913\" title=\"Abelson leukemia virus\">ABL<\/abbr>-negative drug-treatable adolescent and young adult population.<\/li>\n<li>Second-line <abbr data-abbreviation-entity=\"5618\" title=\"B-cell receptor\">BCR<\/abbr>&#8211;<abbr data-abbreviation-entity=\"7913\" title=\"Abelson leukemia virus\">ABL<\/abbr>-positive drug-treatable pediatric population.<\/li>\n<li>Second-line <abbr data-abbreviation-entity=\"5618\" title=\"B-cell receptor\">BCR<\/abbr>&#8211;<abbr data-abbreviation-entity=\"7913\" title=\"Abelson leukemia virus\">ABL<\/abbr>-negative drug-treatable pediatric population.<\/li>\n<li>Third- and fourth-line <abbr data-abbreviation-entity=\"5618\" title=\"B-cell receptor\">BCR<\/abbr>&#8211;<abbr data-abbreviation-entity=\"7913\" title=\"Abelson leukemia virus\">ABL<\/abbr>-positive drug-treatable adolescent and young adult population.<\/li>\n<li>Third- and fourth-line <abbr data-abbreviation-entity=\"5618\" title=\"B-cell receptor\">BCR<\/abbr>&#8211;<abbr data-abbreviation-entity=\"7913\" title=\"Abelson leukemia virus\">ABL<\/abbr>-negative drug-treatable adolescent and young adult population.<\/li>\n<li>Third- and fourth-line <abbr data-abbreviation-entity=\"5618\" title=\"B-cell receptor\">BCR<\/abbr>&#8211;<abbr data-abbreviation-entity=\"7913\" title=\"Abelson leukemia virus\">ABL<\/abbr>-positive drug-treatable older adult population.<\/li>\n<li>Third- and fourth-line <abbr data-abbreviation-entity=\"5618\" title=\"B-cell receptor\">BCR<\/abbr>&#8211;<abbr data-abbreviation-entity=\"7913\" title=\"Abelson leukemia virus\">ABL<\/abbr>-negative drug-treatable older adult population.<\/li>\n<li>\u2026 and many more (details available upon request).<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-250090","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-acute-lymphoblastic-leukemia","biopharma-therapy-areas-hematological-malignancies","biopharma-therapy-areas-hematology","biopharma-product-epidemiology","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250090","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250090\/revisions"}],"predecessor-version":[{"id":281840,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/250090\/revisions\/281840"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=250090"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}